The recommended treatment for O6-methylguanine-DNA methyltransferase (MGMT) promoter unmethylated glioblastoma (Glioblastoma) is radiation therapy with concurrent/adjuvant temozolomide (TMZ). However, it is well known that the clinical benefit from TMZ is lower in these patients.
Waiting time after surgery and overall time data do not indicate a relevant time factor in the treatment of glioblastoma multiforme in a large contemporary single-center cohort. Although a study was limited by its retrospective nature, its results indicate that short delays of postoperative radiochemotherapy, e.g. for screening of a patient for a clinical trial, may be uncritical 1).